NCT06773897 Rutgers University Study of the Genetics of Breast Cancer.
| NCT ID | NCT06773897 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rutgers, The State University of New Jersey |
| Condition | Breast Cancer Risk |
| Study Type | OBSERVATIONAL |
| Enrollment | 25,000 participants |
| Start Date | 2024-04-15 |
| Primary Completion | 2028-04-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 25,000 participants in total. It began in 2024-04-15 with a primary completion date of 2028-04-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn more about how genes impact the risk of breast cancer. Anyone 18 or older living in the US is eligible, and a diagnosis of cancer is NOT required. Study participation is online, and it takes about 20 minutes to complete health surveys and request a saliva collection kit sent through US mail. In return, study participants may opt to receive information about their genetic ancestry at no cost.
Eligibility Criteria
Inclusion Criteria: * age 18 years or older * currently living in the United States * able to understand and follow written instructions in English * have access to the internet and a computer, laptop, tablet or smart phone * willing to provide written informed consent for participation * willing to provide DNA via a saliva sample using a collection kit mailed to the study participant's home * willing to complete a survey with questions about health related to the study of breast cancer. Exclusion Criteria: * Not able to meet or fulfill any of the inclusion criteria
Contact & Investigator
Tara Matise, Ph.D.
PRINCIPAL INVESTIGATOR
Rutgers, The State University of New Jersey
Frequently Asked Questions
Who can join the NCT06773897 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer Risk. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06773897 currently recruiting?
Yes, NCT06773897 is actively recruiting participants. Contact the research team at rugcc@rutgers.edu for enrollment information.
Where is the NCT06773897 trial being conducted?
This trial is being conducted at Piscataway, United States.
Who is sponsoring the NCT06773897 clinical trial?
NCT06773897 is sponsored by Rutgers, The State University of New Jersey. The principal investigator is Tara Matise, Ph.D. at Rutgers, The State University of New Jersey. The trial plans to enroll 25,000 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.